Keros Therapeutics Competitors and Similar CompaniesClear all
Keros Therapeutics's competitors and similar companies include Capricor Therapeutics, Astellas Gene Therapies, Regulus Therapeutics and Imara.
 Keros Therapeutics Keros Therapeutics is a biotechnology company that develops therapeutics to treat a wide range of patients with disorders that are linked to dysfunctional signaling of the transforming growth factor-beta. |  Capricor Therapeutics Capricor Therapeutics is a biotechnology company focused on the discovery, development & commercialization of first-in-class therapeutics for the treatment of diseases. |  Astellas Gene Therapies Astellas Gene Therapies (formerly known as Audentes Therapeutics) is a biotechnology company that employs gene therapy technology to develop treatments for people with rare muscle diseases. |  Regulus Therapeutics Regulus Therapeutics is a biopharmaceutical company involved in the R&D of high-impact medicines based on microRNAs. |  Imara Imara is a company, dedicated to developing novel therapeutics for people living with sickle cell disease and other hemoglobinopathies. | |
Founding Date | Founding Date 2015 | Founding Date 2005 | Founding Date 2013 | Founding Date 2007 | Founding Date 2015 |
Type | Type Public | Type Public | Type Subsidiary | Type Public | Type Public |
Tags | |||||
Locations | Locations Lexington, US HQ South Wharf, AU | Locations Beverly Hills, US HQ | Locations San Francisco, US HQ | Locations San Diego, US HQ | Locations Boston, US HQ |
Employees | Employees 1365% increase | Employees 1854% decrease | Employees 4061% decrease | Employees 2462% decrease | Employees 20 |
Valuation ($) | Valuation ($) 2.3 b | Valuation ($) 998.5 m | Valuation ($) N/A | Valuation ($) 105.4 m | Valuation ($) 166.1 m |
Financial | |||||
Revenue (est.) | Revenue (est.) $3.6m (FY, 2024) | Revenue (est.) $22.3m (FY, 2024) | Revenue (est.) N/A | Revenue (est.) N/A | Revenue (est.) N/A |
Net income | Net income ($187.4m) (FY, 2024) | Net income ($40.5m) (FY, 2024) | Net income ($128.8m) (FY, 2018) | Net income ($46.4m) (FY, 2024) | Net income ($89m) (FY, 2024) |
Funding | |||||
Total funding raised | Total funding raised $ 90m | Total funding raised $ 78.5m | Total funding raised $ 180m | Total funding raised $ 10m | Total funding raised $ 94m |
For sources of this data, please see the company profile
View Company Profiles
Capricor Therapeutics
HQ
Beverly Hills, US
Employees
18
Capricor Therapeutics is a biotechnology company focused on the discovery, development & commercialization of first-in-class therapeutics for the treatment of diseases.
View companyAstellas Gene Therapies
HQ
San Francisco, US
Astellas Gene Therapies (formerly known as Audentes Therapeutics) is a biotechnology company that employs gene therapy technology to develop treatments for people with rare muscle diseases.
View companyRegulus Therapeutics
HQ
San Diego, US
Employees
24
Regulus Therapeutics is a biopharmaceutical company involved in the R&D of high-impact medicines based on microRNAs.
View companyImara
HQ
Boston, US
Employees
20
Imara is a company, dedicated to developing novel therapeutics for people living with sickle cell disease and other hemoglobinopathies.
View company